newsfilter
← Latest News
Business Wire·

Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole

Upcoming PDUFA date of September 23, 2023 Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense,